Long-Term Survival in Unfavourable-Risk mRCC Patients After Intratumoral Administration of a Cell-Based Allogeneic Vaccine

Journal for ImmunoTherapy of Cancer - United Kingdom
doi 10.1186/2051-1426-3-s2-p438

Related search